Research and Innovation Action (RIA)
LifeChamps is funded by the EU’s Horizon 2020 Research and Innovation Programme. Grant Agreement No 875329.
Jan 2020 – Dec 2022 (3 Years)
Aristotle University of Thessaloniki, GreeceVIEW PARTNERS >
Aristotle University of Thessaloniki, Greece
Altran Portugal SA, Portugal
Salumedia Tecnologías, S.L.U., Spain
Universitat Politècnica de València, Spain
Academic Primary Health Care Centre, UK
Karolinska Institutet, Sweden
Cyberlens BV, Netherlands
Health Research Institute Hospital La Fe, Spain
University of Glasgow, UK
European Cancer Patient Coalition, Belgium
Massive Dynamic Sweden AB, Sweden
Why it matters
LifeChamps delivers a novel, context-aware and large-scale analytics framework capable of delivering multi-dimensional Quality of Life (QOL) support to all the different cancer life champions during and after their treatments. LifeChamps is providing support to middle aged and older (pre-frail and frail) cancer patients, as well as their caregivers and healthcare professionals, with an integrated Big Data-driven solution capable to improve their QOL via a timely and more accurate clinical decision support at the point of care. Its Artificial Intelligence (AI) and analytics engine, running both at the cloud and at the mobile edge, can determine accurately which factors affect the oncological patients’ QOL the most, during and after their treatment. Furthermore, complemented by a health recommender system LifeChamps offers personalized healthcare services (such as symptom monitoring, treatment and rehabilitation) to these patients and their caregivers. Finally, a multi-factorial frailty model will allow to stratify sub-clinical frail groups of geriatric cancer patients towards more personalized treatment.
‘”The steady increase in life expectancy, mean age and cancer survivorship across the developed countries together with evidence from cancer and geriatrics care research bring forward the urgent need to deal with the “age issue” as a key component of global cancer care strategies. In 2012, an estimated 6.7 million new cases of cancer were diagnosed in adults aged 65 years and older, representing 47.5% of the total number of new cancer cases worldwide while 8% of the world population in that time was aged 65 years and older, Lifechamps aim is to address this.’’
Robert Greene, ECPC Board Member
What ECPC does
In this project, the European Cancer Patient Coalition (ECPC) will lead liaison and interaction with relevant stakeholders from industry, SMEs, patients, healthcare professionals and policy makers at EU and country level. ECPC will also participate in the identification/establishment of the health needs, priority outcomes, and care requirements of end-users/stakeholders at the post-cancer treatment period, as well as their views, preferences and expectations from the developed LifeChamps components.
This project is funded by the European Union